{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:44:41Z","timestamp":1790808281107,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00066-026-02507-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:05:27Z","timestamp":1770041127000},"page":"921-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes and PSA kinetics after Magnetic Resonance Image-Guided Stereotactic Body Radiotherapy (MRgSBRT) for prostate cancer"],"prefix":"10.1007","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-2356","authenticated-orcid":false,"given":"Ceren","family":"Atahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Ugurluer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorkem","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neris","family":"Dincer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edanur","family":"Celebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Atalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meric","family":"Sengoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ufuk","family":"Abacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Riza Kural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enis","family":"Ozyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"3","key":"2507_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/J.EURURO.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer\u00a0EJ et\u00a0al (2025) Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol 87(3):302\u2013313. https:\/\/doi.org\/10.1016\/J.EURURO.2024.11.013","journal-title":"Eur Urol"},{"issue":"16","key":"2507_CR2","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ejca.2015.07.019","volume":"51","author":"RF Wolff","year":"2015","unstructured":"Wolff\u00a0RF et\u00a0al (2015) A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer 51(16):2345\u20132367. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.019","journal-title":"Eur J Cancer"},{"issue":"8","key":"2507_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley\u00a0D et\u00a0al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047\u20131060. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"2507_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King\u00a0CR, Brooks\u00a0JD, Gill\u00a0H, Presti\u00a0JC (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Adv Radiat Oncol 82(2):877\u2013882. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2507_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2018.8006","author":"AU Kishan","year":"2019","unstructured":"Kishan\u00a0AU et\u00a0al (2019) Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2018.8006","journal-title":"JAMA Netw Open"},{"issue":"10196","key":"2507_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A et\u00a0al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 394(10196):385\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6","journal-title":"The Lancet"},{"key":"2507_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans\u00a0C et\u00a0al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Clin Transl Radiat Oncol 147:92\u201398. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"2507_CR8","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","volume":"117","author":"N van As","year":"2023","unstructured":"van As\u00a0N et\u00a0al (2023) 5\u2011Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer. Adv Radiat Oncol 117(4):e2\u2013e3. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.027","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2507_CR9","unstructured":"Spratt DE et\u00a0al (2025) NCCN Guidelines Version 1.2026 Prostate Cancer NCCN Guidelines Panel Disclosures. www.nccn.org\/home\/. Accessed 3.9.2025"},{"issue":"3","key":"2507_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan\u00a0AU et\u00a0al (2023) Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol 9(3):365\u2013373. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558","journal-title":"JAMA Oncol"},{"issue":"5","key":"2507_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/J.IJROBP.2023.12.035","volume":"118","author":"J Neylon","year":"2024","unstructured":"Neylon\u00a0J et\u00a0al (2024) Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys 118(5):1181\u20131191. https:\/\/doi.org\/10.1016\/J.IJROBP.2023.12.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1117","key":"2507_CR12","doi-asserted-by":"publisher","DOI":"10.1259\/BJR.20200696","volume":"94","author":"G Ugurluer","year":"2020","unstructured":"Ugurluer\u00a0G et\u00a0al (2020) Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Br J Radiol 94(1117):20200696. https:\/\/doi.org\/10.1259\/BJR.20200696","journal-title":"Br J Radiol"},{"issue":"1","key":"2507_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.eururo.2005.04.007","volume":"48","author":"F Akyol","year":"2005","unstructured":"Akyol\u00a0F, Ozyigit\u00a0G, Selek\u00a0U, Karabulut\u00a0E (2005) PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol Oncol 48(1):40\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.007","journal-title":"Eur Urol"},{"key":"2507_CR14","unstructured":"\u201cTransient elevation of serum prostate-specific antigen following (125)I\/(103)Pd brachytherapy for localized prostate cancer - PubMed.\u201d Accessed: Jul. 16, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/10875459\/"},{"key":"2507_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2023.1151256\/BIBTEX","volume":"13","author":"O Gelbart Pridan","year":"2023","unstructured":"Gelbart Pridan\u00a0O et\u00a0al (2023) Outcome of the first 200 patients with prostate cancer treated with MRI-Linac at Assuta MC. Front Oncol 13:1151256. https:\/\/doi.org\/10.3389\/FONC.2023.1151256\/BIBTEX","journal-title":"Front Oncol"},{"issue":"17","key":"2507_CR16","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton\u00a0CN et\u00a0al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J\u00a0Clin Oncol 35(17):1884\u20131890. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"2507_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci\u00a0L et\u00a0al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(16)30070-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"2507_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000534017","volume":"102","author":"MS Schaulin","year":"2024","unstructured":"Schaulin\u00a0MS, Delouya\u00a0G, Zwahlen\u00a0D, Taussky\u00a0D (2024) Tracing the Evolution of Prostate Brachytherapy in the 20th Century. Oncology 102(3):283\u2013290. https:\/\/doi.org\/10.1159\/000534017","journal-title":"Oncology"},{"issue":"4","key":"2507_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","volume":"67","author":"BL Madsen","year":"2007","unstructured":"Madsen\u00a0BL, Hsi\u00a0RA, Pham\u00a0HT, Fowler\u00a0JF, Esagui\u00a0L, Corman\u00a0J (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5\u202fGy in five fractions for localized disease: First clinical trial results. Adv Radiat Oncol 67(4):1099\u20131105. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.10.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2507_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson\u00a0WC et\u00a0al (2019) Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Adv Radiat Oncol 104(4):778\u2013789. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2507_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","volume":"86","author":"N van As","year":"2024","unstructured":"van As\u00a0N et\u00a0al (2024) Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE\u2011A Randomised Trial. Eur Urol Oncol 86(6):566\u2013576. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.030","journal-title":"Eur Urol"},{"key":"2507_CR22","unstructured":"\u201cStudy Details | NCT01794403 | Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer | ClinicalTrials.gov.\u201d Accessed: Nov. 23, 2025. [Online]. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT01794403"},{"issue":"7","key":"2507_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","volume":"26","author":"AC Tree","year":"2025","unstructured":"Tree\u00a0AC et\u00a0al (2025) Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 26(7):936\u2013947. https:\/\/doi.org\/10.1016\/S1470-2045(25)00205-0","journal-title":"Lancet Oncol"},{"issue":"5","key":"2507_CR24","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","volume":"113","author":"C Zamboglou","year":"2022","unstructured":"Zamboglou\u00a0C et\u00a0al (2022) PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2\u2011Armed Phase 2 Trial (ARO2020-01). Adv Radiat Oncol 113(5):1025\u20131035. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2507_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110883","author":"SKB Spohn","year":"2025","unstructured":"Spohn\u00a0SKB et\u00a0al (2025) Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01). Clin Transl Radiat Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2025.110883","journal-title":"Radiotherapy and Oncology"},{"key":"2507_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109713","author":"L De Cock","year":"2023","unstructured":"De Cock\u00a0L et\u00a0al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Clin Transl Radiat Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713","journal-title":"Radiotherapy and Oncology"},{"key":"2507_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.radonc.2021.12.037","volume":"167","author":"TM Ma","year":"2022","unstructured":"Ma\u00a0TM et\u00a0al (2022) Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A\u00a0post-hoc analysis of a\u00a0phase\u00a0III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Clin Transl Radiat Oncol 167:203\u2013210. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.037","journal-title":"Radiotherapy and Oncology"},{"issue":"6","key":"2507_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/0284186X.2022.2062682","volume":"61","author":"A Vanhanen","year":"2022","unstructured":"Vanhanen\u00a0A, Reinikainen\u00a0P, Kapanen\u00a0M (2022) Radiation-induced prostate swelling during SBRT of the prostate. Acta Oncol (Madr) 61(6):698\u2013704. https:\/\/doi.org\/10.1080\/0284186X.2022.2062682","journal-title":"Acta Oncol (Madr)"},{"issue":"4","key":"2507_CR29","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","volume":"64","author":"ME Ray","year":"2006","unstructured":"Ray\u00a0ME et\u00a0al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Adv Radiat Oncol 64(4):1140\u20131150. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.07.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2507_CR30","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/J.IJROBP.2008.12.067","volume":"75","author":"MJ Zelefsky","year":"2009","unstructured":"Zelefsky\u00a0MJ et\u00a0al (2009) Postradiotherapy 2\u2011Year Prostate-Specific Antigen Nadir as a Predictor of Long-Term Prostate Cancer Mortality. Int J Radiat Oncol Biol Phys 75(5):1350\u20131356. https:\/\/doi.org\/10.1016\/J.IJROBP.2008.12.067","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2507_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.UROLOGY.2006.08.1056","author":"R ME","year":"2006","unstructured":"ME\u00a0R et\u00a0al (2006) Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. https:\/\/doi.org\/10.1016\/J.UROLOGY.2006.08.1056","journal-title":"Urology"},{"issue":"5","key":"2507_CR32","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0022-5347(05)64282-6","volume":"168","author":"CJ Rosser","year":"2002","unstructured":"Rosser\u00a0CJ et\u00a0al (2002) The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. Journal of Urology 168(5):2001\u20132005. https:\/\/doi.org\/10.1016\/S0022-5347(05)64282-6","journal-title":"Journal of Urology"},{"issue":"4","key":"2507_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0360-3016(01)01557-7","volume":"50","author":"AL Hanlon","year":"2001","unstructured":"Hanlon\u00a0AL, Pinover\u00a0WH, Horwitz\u00a0EM, Hanks\u00a0GE (2001) Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50(4):845\u2013849. https:\/\/doi.org\/10.1016\/S0360-3016(01)01557-7","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2507_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ijrobp.2005.07.960","volume":"64","author":"JP Ciezki","year":"2006","unstructured":"Ciezki\u00a0JP et\u00a0al (2006) PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Adv Radiat Oncol 64(2):512\u2013517. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.07.960","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2507_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijrobp.2009.10.066","volume":"79","author":"A Kirilova","year":"2011","unstructured":"Kirilova\u00a0A, Damyanovich\u00a0A, Crook\u00a0J, Jezioranski\u00a0J, Wallace\u00a0K, Pintilie\u00a0M (2011) 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA \u2018bounce\u2019 following 125iodine brachytherapy. Adv Radiat Oncol 79(2):371\u2013378. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.066","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2507_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.radonc.2018.08.011","volume":"129","author":"L \u00c5str\u00f6m","year":"2018","unstructured":"\u00c5str\u00f6m\u00a0L, Sandin\u00a0F, Holmberg\u00a0L (2018) Good prognosis following a\u00a0PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer. Clin Transl Radiat Oncol 129(3):561\u2013566. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.011","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"2507_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/bjc.2016.171","volume":"115","author":"Y Yamamoto","year":"2016","unstructured":"Yamamoto\u00a0Y et\u00a0al (2016) Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. British Journal of Cancer 115(2):195\u2013202. https:\/\/doi.org\/10.1038\/bjc.2016.171","journal-title":"British Journal of Cancer"},{"key":"2507_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/J.RADONC.2024.110642\/ASSET\/44C1B977-04DB-4E0D-9145-2493FF76135B\/MAIN.ASSETS\/GR3.JPG","author":"CS Dejonckheere","year":"2025","unstructured":"Dejonckheere\u00a0CS et\u00a0al (2025) Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis. Radiotherapy and Oncology. https:\/\/doi.org\/10.1016\/J.RADONC.2024.110642\/ASSET\/44C1B977-04DB-4E0D-9145-2493FF76135B\/MAIN.ASSETS\/GR3.JPG","journal-title":"Radiotherapy and Oncology"},{"key":"2507_CR39","unstructured":"\u201cESTRO 2025 - Abstract Book.\u201d Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/user-swndwmf.cld.bz\/ESTRO-2025-Abstract-Book"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02507-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:20:15Z","timestamp":1787739615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02507-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02507-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Atahan, G.\u00a0Ugurluer, G.\u00a0Gungor, N.\u00a0Dincer, E.\u00a0Celebi, A.\u00a0Gul, B.\u00a0Atalar, M.\u00a0Sengoz, U.\u00a0Abacioglu, A.\u00a0Riza Kural and E.\u00a0Ozyar declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}